cenicriviroc (TBR-652) / Dong-A, AbbVie, Takeda  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cenicriviroc (TBR-652) / Takeda, AbbVie
AURORA, NCT03028740 / 2016-004566-26: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

Checkmark From AURORA trial [Trial terminated]
Jan 2021 - Jan 2021: From AURORA trial [Trial terminated]
Terminated
3
1778
Europe, Canada, US, RoW
Placebo, Cenicriviroc, CVC
Tobira Therapeutics, Inc.
Nonalcoholic Steatohepatitis
01/21
03/21
ACTIV-1 IM, NCT04593940: Immune Modulators for Treating COVID-19

Completed
3
1971
US, RoW
Infliximab, remicade, Abatacept, orencia, Remdesivir, cenicriviroc (closed to enrollment as of 3-Sep-2021)
Daniel Benjamin, National Center for Advancing Translational Sciences (NCATS), Biomedical Advanced Research and Development Authority
Covid19
01/22
03/22

Download Options